Total amount: € 0,00
Indexed/Abstracted in: BIOSIS Previews, Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,632
Online ISSN 1827-191X
Pavie A. J., Nzomvuama A. N., Bonnet N., Bors V. H., Gandjbakhch I.
From the Thoracic and Cardiovascular Surgery Department Hôpital ''La Pitié-Salpétrière'', Paris, France
Background. This paper presents the analysis of clinical results of the composite porcine Labcor™ bioprosthesis in the replacement of aortic valves in the elderly.
Methods. This retrospective study was carried out in the Thoracic and Cardiovascular Surgical Department, La Pitié-Salpétrière Hospital, Paris, for replacement of calcified, stenosed aortic valves between 1988 and 1995. It involved a series of 100 patients aged 70 and over (mean: 80±5 years ranging from 70 to 90). There were 63 female and 37 male patients. Preoperatively, five patients were in NYHA Class I, 23 in Class II, 65 in Class III and 7 in Class IV.
Results. Fifteen patients died in the early postoperative stage and 13 during the follow-up period. There was no evidence of valve failure. The average follow-up was 32 months and the actuarial survival rate at 5 years was 74±5%. Complications due to bleeding occurred in 3 patients taking anticoagulant treatment. There were neither valvular thrombosis nor embolism. Two patients presented with prosthetic endocarditis. Two patients received a reoperation because of leakage (1 septic). The five-year follow-up showed that 96% of patients did not require further surgery. When this study was completed, 83% of patients were in Class I or II versus 71% in Class III or IV prior to surgery.
Conclusions. In the early/middle follow-up term, the results obtained when replacing the aortic valve with the composite Labcor™ bioprosthesis in the elderly are satisfying. Nevertheless, further long-term assessment is needed.